<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509405</url>
  </required_header>
  <id_info>
    <org_study_id>316/06</org_study_id>
    <secondary_id>NFP 53: 4053-110259</secondary_id>
    <nct_id>NCT00509405</nct_id>
  </id_info>
  <brief_title>Effect of Neutralization of Endogenous Acid Production on BMD and Bone Microarchitectural</brief_title>
  <official_title>Effect of Neutralization of Endogenous Acid Production on Bone Mineral Density and Microarchitectural Composition of Bone in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Baselland Bruderholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Baselland Bruderholz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Neutralization of acid production induced by the Western diet with oral
      administration of potassium citrate increases bone mineral density and bone mass as well as
      skeletal muscle mass and strength in elderly people (&gt; 65y).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will perform a prospective, randomized, placebo-controlled trial evaluating the effect of
      K citrate on bone mineral density, microarchitectural composition of bone,nutritional
      parameters, lean body mass, parameters of skeletal muscle mass and strength, 24h and exercise
      induced blood pressure changes in otherwise healthy, elderly ambulatory subjects of both
      genders.

      Potassium citrate (60 mEq) is supplied as tablets with a wax matrix (10 mEq of citrate per
      tablet) and ingested in three doses/day. All subjects will receive daily oral 500 mg of
      calcium and 400 IU of vitamin D to ensure adequate calcium and vitamin D supply.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMD at L2-L4 by DEXA and microarchitectural composition of bone in both tibias and radius</measure>
    <time_frame>12 and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on BMD at hip and total body Effect on 24h ambulatory blood pressure</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on skeletal muscle mass and strength</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on left ventricular muscle mass</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on carotid media-intima thickness</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxia-induced endothelial vasorelaxation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>potassium citrate</intervention_name>
    <description>6 times 10 mEq per day, oral for 24 months</description>
    <arm_group_label>Potassium citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 65 to 80y, tscores at L2-L4 0 to -2.5

        Exclusion Criteria:

          -  Treated or necessity to treat low BMD (t-score L2 to L4 &lt;-2.5)

          -  Any major medical illness that would possibly need hospitalization and/or be followed
             by foreseeable complications within 12 months and/or have a life-expectancy of less
             than 5 years

          -  Stable serum creatinine &gt; 150 umol/l and/or known Type IV renal-tubular acidosis
             (hyperkalemia)

          -  vegetarians

          -  concommitant drug prescriptions: systemic and topical glucocorticoids, systemically
             acting estrogens (topical allowed): both within the last 6 months. antiosteoporosis
             drugs: bisphosphoponates, fluoride, calcitonin, all within the previous 12 months.

          -  vitamin D deficiency at screening visit

          -  technical difficulties to delineate bone area of interest during the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto Krapf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Kantonsspital Bruderholz, CH-4101 Bruderholz/Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz/Basel</city>
        <state>BL</state>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.medicalforum.ch</url>
    <description>check in archive for &quot;essen wir zu sauer&quot;</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Baselland Bruderholz</investigator_affiliation>
    <investigator_full_name>Reto Krapf</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Endogenous acid production</keyword>
  <keyword>metabolic acidosis</keyword>
  <keyword>potassium citrate</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>sarcopenia</keyword>
  <keyword>hypertension</keyword>
  <keyword>Effect of potassium citrate on bone mineral density and bone mass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

